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Early infant diagnosis (EID) and prompt linkage to care are critical to minimise the high mor-
bidity and mortality associated with infant HIV infection. Attrition in the “EID cascade” is
common; however, point-of-care (POC) EID assays with same-day result could facilitate
prompt linkage of HIV-infected infant to treatment. Despite a number of POC EID assays in
development, few have been independently evaluated and data on new technologies are
urgently needed to inform policy.
Methods
We compared Alere q 1/2 Detect POC system laboratory test characteristics with the local
standard of care (SOC), Roche CAP/CTM HIV-1 qualitative PCR in an independent labora-
tory-based evaluation in Cape Town, South Africa. Routinely EID samples collected
between November 2013 and September 2014 were each tested by both SOC and POC
systems. Repeat testing was done to troubleshoot any discrepancy between POC and
SOC results.
Results
Overall, 1098 children with a median age of 47 days (IQR, 42–117) were included. Birth
PCR (age <7 days) comprised of 8% (n = 92) tests while 56% (n = 620) of children tested as
part of routine EID (ages 6–14 weeks). In the overall direct comparison, Alere q Detect
achieved sensitivity of 95.5% (95% CI, 91.7–97.9%) and a specificity of 99.8% (95% CI,
99.1–100%). Following repeat testing of discordant samples and exclusion of any inconclu-
sive results, the POC assay sensitivity and specificity were 96.9% (95% CI 93.4–98.9%)
and 100% (lower 95% CI 98%) respectively. Among birth PCR tests the POC assay had
slightly lower sensitivity (93.3% vs 96.5% in routine EID) and higher assay error rate (10%
vs 5% in samples of older children, p = 0.04).
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Conclusion
Our results indicate this POC assay performs well for EID in the laboratory. The high speci-
ficity and thus high positive predictive value would suggest a positive POC result may be
adequate for immediate infant ART initiation. While POC testing for EID may have particular
utility for birth testing at delivery facilities, the lower sensitivity and error rate requires further
attention, as does field implementation of POC EID technologies in other clinical care
settings.
Introduction
Perinatal HIV infection is associated with high levels of morbidity and mortality in the first
year of life [1]. Early infant HIV diagnosis (EID) and prompt referral for treatment improves
survival and subsequent development [2, 3] but access to EID is severely limited in many set-
tings. Across most of the world the standard-of-care (SOC) for EID uses polymerase chain
reaction (PCR) testing that typically requires costly equipment and highly skilled operators. In
resource-limited settings, PCR testing for EID is therefore restricted to centralised specialised
molecular laboratories located in major urban centres.
This specialised, centralised approach to EID testing creates a complex cascade of logistical
steps between sampling, testing, return of results, infant follow-up, linkage to care and ART
initiation [4]. The EID cascade not only prolongs the turnaround time for infant management
but also leads to significant attrition at each step. In particular, adequate access of laboratory
testing does not always result in linkage to care and ART initiation. In 2010, only 71% of PCR
positive infants in South Africa were linked to subsequent ART service and for those who were
linked to care and there was a median delay to treatment of 33 days [5]. This attrition is even
more pronounced in other parts of the world, with 22%, 37% and 38% of HIV infected infant
were initiated on ART in Senegal, Uganda and Cambodia, respectively [6]. In Botswana a
review of 8 years of EID showed that only 41% of PCR positive infants children were alive and
on antiretroviral therapy, 39% had died, and 20% were either lost to follow-up, had transferred,
or their mothers declined ART [7]. Cumulatively, the barriers to laboratory-based EID testing
mean that only an estimated 39% of HIV-exposed infants in the WHO EID priority countries
underwent appropriate testing in 2013 [8].
Meanwhile, advances in prevention of mother-to-child transmission of HIV (PMTCT) dur-
ing the past decade have resulted in both improved coverage [9] and more efficacious regimens
[10] for PMTCT. These advances, particularly in coverage of antiretroviral therapy (ART) for
HIV-infected mothers and antiretroviral prophylaxis for HIV-exposed infants, are reshaping
EID in terms of optimal time of testing. Specifically, more potent perinatal PMTCT regimens
have resulted in drops in HIV transmission risks both intrapartum and postpartum through
breastfeeding; as the perinatal HIV transmission rate drops, there is an increasing focus on
identifying intrauterine transmission with PCR at birth to further reduce infant mortality [11,
12]. In this context, the turnaround time from sampling to result reporting is becoming even
more important as referral to care in the immediately postnatal setting may depend heavily on
the rapid availability of PCR results.
Point-of-care (POC) technologies are widely considered as a possible solution to these kinds
of programmatic challenges in delivering HIV prevention and treatment services. For example,
rapid HIV antibody tests are recommended by the World Health Organisation (WHO) and
used widely to diagnose adult HIV infection and initiate ART in resource-constrained settings
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[13], and point-of-care CD4 enumeration has enabled staging of new HIV diagnoses to
improve linkage to care and initiation of ART in contexts with limited laboratory access [14].
In the case of EID, same-day, POC HIV PCR testing could reduce attrition and delays across
the EID cascade by removing the time and logistical complexities related to specimen trans-
port, testing, return of results and recall of patients. In turn, POC EID testing has the potential
to greatly enhance infant treatment outcomes.
Several POC technologies for EID are being developed, but few are at an advanced stage of
development or have been independently evaluated [15]. The Alere q HIV-1/2 Detect system
(Alere Healthcare, Waltham, Massachusetts, USA) is a cartridge-based qualitative POC nucleic
acid amplification test (NAT) that is designed for POC use and could be used in EID pro-
grammes. We evaluated the performance of the Alere q HIV-1/2 Detect system in a laboratory
setting by comparing its result with the current EID standard of care in South Africa.
Methods
Design
We performed a laboratory-based evaluation of Alere q 1/2 Detect to compare the POC test
performance with the local SOC system for EID PCR. Samples from HIV-exposed children
under 2 years of age undergoing routine HIV PCR testing in Western Cape province of South
Africa between December 2013 and August 2014 were used for this evaluation. Samples came
from children enrolled in various levels of paediatric care ranging from routine EID pro-
gramme in primary care clinics to neonates delivered at maternity hospitals and specialist pae-
diatric services. During the study period, local PMTCT policies called for universal initiation of
lifelong antiretroviral therapy (ART) for all HIV-infected pregnant women regardless of CD4
cell count or HIV diseases stage (per the WHO policy of “Option B+”)[16]. Infant HIV testing
was called for routinely in infants at 6 weeks of age, with testing at birth conducted for infants
considered to be at high risk of HIV infection. During the study period the overall transmission
rate in the province was estimated at approximately 1% [17].
Ethics and consent
The study was approved by the Human Research Ethics Committee of University of Cape
Town Faculty of Health Sciences and the Provincial Government of the Western Cape. The
laboratory evaluation of the POC system is done through testing of routine clinical sample. A
waiver for written informed consent was given because patient identity was delinked from the
samples following the capture of relevant demographic information.
Procedures
Following local practice, infant EDTA specimens (200–500μL) were collected through heel-
prick or venepuncture at health care facilities and whole blood samples were transported the
Groote Schuur Hospital laboratory of the National Health Laboratory Services (GSH-NHLS)
where routine EID PCR is conducted. Whole blood samples are transported and stored at 4°C
and tested within 72 hours of blood draw. Dried blood spots (DBS) were not routinely used in
the local EID testing and thus did not form part of this study. The SOC assay for the study was
version 1 of Roche Cobas AmpliPrep /Cobas TaqMan (CAP/CTM) HIV-1 qualitative assay
(Roche diagnostics, Branchburg, New Jersey, USA), targeting the GAG and LTR region of HIV
genome. The test was performed according to the manufacturer’s instructions. The lower limit
of detection of the assay is 20 copies/ml. Due to local concerns around previously published
reports of false positivity on this assay [17], the laboratory treats a subset of CAP/CTM positive
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result with cycle threshold (CT) values>33 as inconclusive as part of standard operating
procedures.
During the study period the Alere q HIV 1/2 Detect (the POC assay) was performed on 6
different Alere q instruments by 7 trained laboratory staff. For this, 25μl of whole blood was
pipetted from the EDTA tube to the test cartridge. The test takes approximately 55 minutes to
process. The POC result was considered valid when the cartridge built-in controls were passed
by the instrument. When a quality control measure fails due to either sample of instrument
errors, an error code was issued and this data was recorded by the laboratory staff. If sufficient
sample was available, repeat testing of sample with POC assay error was performed.
Sampling
The study sampling was conducted in two phases. First, consecutive specimens were tested on
both the SOC and POC assay in parallel, with staff blinded to test results. Because of the rela-
tively low prevalence of HIV in this context, a second phase of sampling was conducted with
only positive SOC specimens referred for POC testing.
Analysis
Data were analysed using Stata Version 12.0 (Stata Corporation, College Station, Texas, USA).
In analysis, qualitative output of SOC (CAP/CTM) was used in the comparison against the
POC assay. Test performance for all infants, as well as stratified by infant age (with categories
for newborn testing, conducted at<7 days of age, and routine testing, conducted at 6–14
weeks of age) and testing facility (comparing primary care clinics to specialist paediatric care),
was estimated using sensitivity and specificity as well as positive and negative predictive values,
with exact 95% confidence intervals (CI). In addition, cycle threshold (CT) values form the
SOC assay were used as semi-quantitative measures analysed as medians with interquartile
ranges (IQR). POC test error rates were estimated as proportion of total number of samples
tested with exact 95% CI. Throughout, Fisher’s exact tests were used to compare proportions
and rank-sum tests were used to compare medians; all statistical tests are 2-sided at
alpha = 0.05.
Two sets of qualitative analyses are presented (Fig 1). The first test result is based on the first
result produced by both the POC and SOC tests, irrespective of the CT value of the SOC result.
In order to explore the discrepancies of the two assays and possible false positive SOC results, a
final test result that allows for re-testing following inconclusive results was also analysed. In
considering the final HIV test result, wherever the SOC result was reported as inconclusive or
there was a disagreement between SOC and POC assays, further PCR testing on both platforms
was performed pending suitable specimen availability. In the event of a first, inconclusive test
result, a specimen is considered HIV-infected in the final test result when it tested positive sub-
sequently on two different nucleic acid test assays or conclusively SOC assay positive on a dif-
ferent specimen.
This study report conforms to the STAndards for the Reporting of Diagnostic accuracy
studies (STARD).
Results
In total 1193 POC tests from 1131 samples were performed from 1098 children. The findings
from the consecutive and positive-only sampling phases are identical, and reported jointly
here. The demographic characteristics and SOC results for these children are summarised in
Table 1. The median age of tested children was 47 days (IQR, 42–117) with 8% of children
tested as newborns (age<7 days) and 56% of children tested as part of routine EID (ages
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Fig 1. STARD diagnostic study flow diagram. The POC diagnostic accuracy analyses take into account 1) the result of first SOC test result* which is a
direct comparison between the qualitative output of SOC and POC assay according to the manufacturer’s instructions. 2) Final test result which used the best
result following retest for any inconclusive SOC result (CT > 33) and any discordant SOC/POC results. If an infant is conclusively positive on SOC assay in
another sample, or positive on two different nucleic acid tests, the infant is considered positive in final result. Otherwise his/her final result is considered
inconclusive.
doi:10.1371/journal.pone.0152672.g001
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6–14 weeks). Children from primary clinic setting made up of 74% of the total children with
19% of children tested from a specialist paediatric service (n = 204). Overall, 212 of the 1098
(19%) children were positive according to the qualitative output of the SOC assay. However,
13/212 (6%) of these positive samples were interpreted as inconclusive based on CT<33.
In the direct comparison on first test results, 1024/1035 (98.9%) of POC results were concor-
dant with the SOC assay. Nine (0.8%) children tested SOC positive were negative for POC
assay and two (0.2%) SOC negative samples tested positive on the POC assay (Table 2). The
sensitivity of Alere q was 95.5% (95% CI 91.7–97.9%) and the specificity was 99.8% (95% CI
99.1–100%). The median CT value of SOC and POC positive samples was 24.3 (IQR 22.1–
27.6), significantly lower than the median CT value of SOC positive, POC negative samples 34
(IQR 31.1–36.2 p<0.001). After resolving assay discrepancies and inconclusive SOC results
with additional testing, the final test results were available for 1027 samples. Of these, 1021
final test results was correctly identified (99.4% concordance) with no false positive POC PCR
Table 1. Summary study population demographic and facility characteristics by standard of care
result status.
SOC PCR SOC PCR
Positive (%) Negative (%) Total
Total 212 (19%) 886 (81%) 1098
Median age 88 days 46 days 47 days
Age group
<7 days 16 (17%) 76 (83%) 92
7 days to 6 weeks 14 (19%) 58 (81%) 72
6–14 weeks 81(13%) 539 (87%) 620
>14 weeks 101(32%) 213 (68%) 314
Sex
male 88 (17%) 432 (83%) 520
female 117 (21%) 441 (79%) 558
unknown 7 (35%) 13 (65%) 20
Type of facility
primary clinics 114 (14%) 698 (86%) 812
paediatric hospitals 83 (41%) 121 (59%) 204
maternity services 14 (17%) 67 (83%) 81
doi:10.1371/journal.pone.0152672.t001
Table 2. Performance of Alere q Detect HIV-1 (first test) against the standard of care Roche CAP/CTM
HIV-1 PCR.
Roche CAP/CTM HIV-1 PCR
Alere q Detect Positive Negative Total
Positive 192 2 194
Negative 9 832 841
Total 201 834 1035
Compared to the qualitative CAP/CTM HIV-1 PCR result, the first attempt of Alere q achieved a sensitivity
of 95.5% (95%CI 91.7–97.9%) with a positive Likelihood Ratio of 447.5. The specificity in this setting was
99.8% (95% CI 99.1–100%) with a negative Likelihood Ratio of 0.045.
doi:10.1371/journal.pone.0152672.t002
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were found while 6 false negative PCR were present, giving rise to sensitivity and specificity of
96.9% (95% CI 93.4–98.9%%) and 100% (lower 95% CI 98%) respectively (Table 3).
Of the samples tested, 6% (n = 67 samples from 63 children) of all first POC tests resulted in
an error. In a subset of sample (n = 37) retested, 25/37 (68%) resolved after 1 additional test, 6/
37 (16%) errors were resolved after 2 additional test and 6/37 (16%) gave repeated error mes-
sages despite 2 repeat attempts. Ninety percent of the recorded error codes were assay- or sam-
ple-related quality control failure. There were no associations between errors and a particular
instrument or user.
To further evaluate the performance of the POC assay in the context of testing at birth, we
stratified the comparison against final HIV result into three of the follow clinical scenarios:
samples from newborns less than 7 days of age (n = 81), routine early infant diagnosis samples
from primary care clinic between the age 6–14 weeks (n = 543) and samples from symptomatic
infants of all ages from tertiary paediatric facilities (n = 181). The sensitivity of the assay was
reduced to 93.3% (95%CI 68.1–99.8%; LR- 0.067) in the newborn stratum when compared to
sensitivity of 96.5% (95%CI 87.8–99.5%; LR- 0.035) and 97.3% (95%CI 90.7–99.7%; LR- 0.027)
in routine EID samples and symptomatic infants, respectively. A Lowess plot of test sensitivity
across ages at testing in infant samples less or equal to 10 weeks of age (Fig 2) showed that the
sensitivity of the assay appeared lower in the first 2 weeks of life, increasing until around 8
weeks. Assay errors were also more common from samples of the newborns category (10%)
when compared with rest of the samples (6%, p = 0.04)
Discussion
These novel data examine the performance of Alere q HIV1/2 Detect by comparing its result
with a single current standard of care assay testing and after repeat testing. The latter is impor-
tant given potential uncertainty around infant HIV diagnosis using the SOC assay in the con-
text of maternal and/or child antiretroviral use [18,19, 20]. Our results showed that Alere q
HIV 1/2 Detect showed excellent overall concordance with the SOC assay, with overall high
sensitivity and specificity following repeat testing.
We found that the specificity of the test (99.8%) improved to 100%, with no false positive
results detected, when the uncertainty of weakly positive SOC results were resolved through
follow up testing. This small improvement may seem insignificant but in the era of maternal
and infant antiretroviral use for treatment and/or prophylaxis, the incidence of MTCT is
becoming extremely low making false positive results an increasing concern. In our setting
(with an estimated infant HIV infection prevalence of approximately 1%) this increase corre-
sponds to a substantial increase in positive predictive value from 84% to 100%. Thus, maximiz-
ing test specificity is an important feature of any EID platform, and the POC evaluated here
performed well in this regard.
The sensitivity of any NAT is dependent in part on the volume of sample input. While the
25μl input for Alere q HIV1/2 Detect facilitates use for EID, this low sample volume and higher
Table 3. Performance of Alere q Detect HIV-1 in against different gold standards in various scenarios.
Comparison n Sensitivity (95%CI) Specificity (95%CI) LR+ LR-
Versus SOC 1035 95.5% (91.7–97.9%) 99.8% (99.1–100%) 447.5 0.045
Versus final result 1027 96.9% (93.4–98.9%) 100% (98%-100%) N/A 0.031
Versus final result in routine EID 543 96.5% (87.8–99.5%) 100% (99.2%-100%) N/A 0.035
Versus final result in newborn 81 93.3% (68.1–99.8%) 100% (94.6%-100%) N/A 0.067
Versus final result in Specialist paediatric Hospital 181 97.3% (90.7–99.7%) 100% (96.6%-100%) N/A 0.027
doi:10.1371/journal.pone.0152672.t003
Evaluation of the Alere q Detect for Early Infant HIV Diagnosis
PLOS ONE | DOI:10.1371/journal.pone.0152672 March 31, 2016 7 / 11
assay limit of detection may reduce test sensitivity compared to the SOC. The lower median
CT observed here in false negative samples on the POC assay suggests that low copy number
may be a key reason for the SOC positive sample unidentified by the POC assay. The detection
of low copy numbers of HIV is a major challenge facing all EID assays, particularly in the era
of ART prophylaxis for infants.
The reasons for discordant results between POC and SOC platforms require further investi-
gation. Sequencing of HIV isolates in the assay target regions revealed that among the 11 dis-
cordant POC/SOC results, the 5’LTR region of one sample had two rare mutations which
resulted in mismatches with the POC assay reporter (data not shown) which could have
resulted in false negative POC results. In a second sample, HIV GAG sequences revealed three
rare mutations that could have resulted in poor binding of SOC assay probe [21] and false neg-
ative SOC result.
Our study found 6% of samples resulted in assay error in laboratory setting. This is higher
than the accepted error rate on our SOC platform (approximately 2–3%) and points to an
important operational consideration in POC EID testing. Test errors due to failure of quality
control or instrument failure could significantly affect the feasibility and costs of delivering
EID via POC. We note that the vast majority of errors resolved upon retesting, and thus
hypothesize that the errors may be due to specimen collection and/or operator errors. This
issue needs to be thoroughly investigated in future field studies and a step-by-step trouble
shooting guides for different types of errors should be developed prior the implementation of
the assay.
Fig 2. Lowess plot for sensitivity of infant testing in the first 10 weeks of life. The Lowess smoothing plot of POC sensitivity from infant samples across
the age spectrum showed that the POC assay sensitivity is slightly lower in infants tested immediately after birth. The sensitivity improved as age of sampling
increased. The optimal sensitivity was achieved around the routine EID age of 6–10 weeks.
doi:10.1371/journal.pone.0152672.g002
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There are some limitations of this study. The study was conducted in the laboratory and
performed by laboratory staff that is familiar with NAT assays. This means several key ques-
tions around ease of use and performance in the field cannot be addressed. We did not have
access to information on maternal ART use, nor on antiretroviral prophylaxis given to infants,
and thus cannot comment on the potential role of antiretrovirals in influencing EID test
results. Our study also did not include comparison against SOC assay performed on DBS, a
common sample type for early infant diagnosis. As whole blood testing is more sensitive than
DBS, we feel the comparison against DBS will likely be more favourable than our finding
because the low copy target that is missed by the POC in this study may also be missed by the
relatively insensitive DBS assays. The determinations of final infection status for some of the
infants are incomplete due to limited blood samples received and the lack of follow up in many
of these infants. Exclusion of these infants in the final HIV result could affect the analysis,
although a small random group of infants is unlikely to significantly affect our estimate. Finally,
we did not retest all the concordant results between the POC and SOC assay and thus any
shared false positive/negative profile of the two assays would not have been detected. In order
to know the true HIV infection status of infant in the POC assay evaluation, a large scale longi-
tudinal study that include testing of subsequent samples and long term follow up would be
required. Indeed, the 2014 WHO guideline of new strategy for diagnosing HIV infection
among infants [22] highlighted that more thorough evaluation of virological testing in the set-
ting of robust maternal combination antiretroviral regimens, prolonged infant antiviral pro-
phylaxis and improved sensitivity of current HIV DNA- and RNA-based polymerase chain
reaction (PCR) assays. With limited resources, low mother-to-child transmission rate and fre-
quent lost to follow up; this is an important challenge facing all EID assay evaluations.
In conclusion, this study suggests that the Alere q HIV1/2 Detect performed well in a chal-
lenging population with high coverage of maternal ART and infant prophylaxis. The high spec-
ificity of Alere q HIV 1/2 Detect is a very important attribute for POC assays as it provide
confidence for early ART initiation. Although its sensitivity is slightly lower in newborns, the
assay’s performance and potential for POC use hold promise for EID implementation.
Supporting Information
S1 File. Database of study data. This database contains basic study data of all samples tested on
point-of-care assay (Alere q Detect) and standard of care assay (Roche CAP/CTM). In addition
to the qualitative results of both assays, the error code and cycle threshold value were captured
for POC assay failure samples and SOC positive sample respectively. In some cases, individuals
or samples were tested more than once due to either assay failure in the first attempt or discrep-
ancy between POC and SOC assays. The repeat testing is captured under time tested column as
2nd 3rd 4th or 5th retests. Only first attempts were included in the primary analysis of the study.
(XLS)
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